Cart
sales@molnova.com
AZD 4320
CAS No. 1357576-48-7
AZD 4320 ( AZD4320 )
Catalog No. M11468 CAS No. 1357576-48-7
AZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 84 | In Stock |
|
| 5MG | 129 | In Stock |
|
| 10MG | 176 | In Stock |
|
| 25MG | 350 | In Stock |
|
| 50MG | 531 | In Stock |
|
| 100MG | 773 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAZD 4320
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM.
-
DescriptionAZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM; induces caspase-3 cleavage and cell death in both Bcl-2-driven (SuDHL4, GI50 <50 nM) and Bcl-xL-driven (SuDHL8, GI50 <50 nM) diffuse large B-cell lymphoma (DLBCL) cell lines; results in complete and sustained (>24 days) tumor regressions in a mouse RS4;11 acute lymphocytic leukemia xenograft model (20 mg/kg, i.v.).
-
SynonymsAZD4320
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1357576-48-7
-
Formula Weight945.53
-
Molecular FormulaC45H48ClF3N4O7S3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NS(=O)(C1=CC=C(N[C@H](CCN(CCO)C)CSC2=CC=CC=C2)C(S(=O)(C(F)(F)F)=O)=C1)=O)C3=CC=C(N4CCC([C@H](C5=CC=CC=C5C6=CC=C(Cl)C=C6)O)CC4)C=C3
-
Chemical Name4-(4-((R)-(4'-chloro-[1,1'-biphenyl]-2-yl)(hydroxy)methyl)piperidin-1-yl)-N-((4-(((R)-4-((2-hydroxyethyl)(methyl)amino)-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ashkenazi A, et al. Nat Rev Drug Discov. 2017 Apr;16(4):273-284.
2. Hennessy, E. J. et al. Discovery of potent inhibitors of the antiapoptotic proteins Bcl-2 and Bcl-xL, resulting in the identification of a clinical candidate for the treatment of cancer (AZD4320). ACS Medicinal Chemistry annual meeting 2015.
2. Hennessy, E. J. et al. Discovery of potent inhibitors of the antiapoptotic proteins Bcl-2 and Bcl-xL, resulting in the identification of a clinical candidate for the treatment of cancer (AZD4320). ACS Medicinal Chemistry annual meeting 2015.
molnova catalog
related products
-
BCL6 inhibitor 7
A potent BCL6 protein-protein interaction inhibitor with Kd of 78 nM; exhibits an efficacy in cell-free and cellular PPI assays.
-
trans-Ferulic acid
Trans-Ferulic acid causes the phosphorylation of β-catenin resulting in proteasomal degradation of β-catenin and increases the expression of pro-apoptotic factor Bax and decreases the expression of pro-survival factor survivin.trans-Ferulic acid exert both anti-proliferation and anti-migration effects in the human lung cancer cell line H1299.
-
Lisaftoclax
Bcl-2/Bcl-xl inhibitor 1 is a dual Bcl-2 and Bcl-xl inhibitor (IC50s: 2 nM and 5.9 nM for Bcl-2 and Bcl-xl) with anti-tumor activity. It is extracted from patent WO2018027097A1.
